Resultado de búsqueda
Hace 22 horas · Inicio. Vertex Pharmaceuticals ha presentado una demanda contra el gobierno de los Estados Unidos debido a restricciones federales que impiden que la empresa ofrezca asistencia para la preservación de la fertilidad a los pacientes cubiertos por Medicaid que se someten a su innovador tratamiento para la anemia falciforme, Casgevy.
Hace 22 horas · CRISPR Therapeutics could start reporting product revenue soon. Vertex Pharmaceuticals ( VRTX -0.23%) has made it to the major leagues in the world of biotech. The company is the leading maker of ...
Hace 22 horas · Mientras Vertex Pharmaceuticals (NASDAQ: VRTX) amplía su asociación con Genomics plc, los inversores pueden estar evaluando la salud financiera de la empresa y su rendimiento en el mercado.
Hace 22 horas · In return for its technology, Orum will receive an upfront payment of $15 million from Vertex, with the potential to earn close to $1 billion more. (Harry Cooper Photography/Getty Images) Vertex ...
Hace 22 horas · Vertex Pharmaceuticals on Monday filed a lawsuit that, if successful, would allow it to offer fertility support and treatment services for patients receiving its gene editing therapy Casgevy (exagamglogene autotemcel) who are insured through the federal government.. The lawsuit challenges an oral decision by the Department of Health and Human Services’ (HHS) Office of the Inspector General ...
Hace 1 día · Vertex Pharmaceuticals sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for patients who are prescribed its gene ...
Hace 1 día · Charles Krupa/AP. O ne of the makers of Casgevy — the world’s first CRISPR-based medicine — filed a lawsuit Monday intended to clear the way for the company to pay for fertility preservation ...
